337 related articles for article (PubMed ID: 37088421)
1. Non-alcoholic fatty liver disease is associated with greater risk of 30-day hospital readmission in the United States (U.S.).
Paik JM; Eberly KE; Kabbara K; Harring M; Younossi Y; Henry L; Verma M; Younossi ZM
Ann Hepatol; 2023; 28(4):101108. PubMed ID: 37088421
[TBL] [Abstract][Full Text] [Related]
2. Alcoholic liver disease confers a worse prognosis than HCV infection and non-alcoholic fatty liver disease among patients with cirrhosis: An observational study.
Marot A; Henrion J; Knebel JF; Moreno C; Deltenre P
PLoS One; 2017; 12(10):e0186715. PubMed ID: 29077714
[TBL] [Abstract][Full Text] [Related]
3. Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation.
Goldberg D; Ditah IC; Saeian K; Lalehzari M; Aronsohn A; Gorospe EC; Charlton M
Gastroenterology; 2017 Apr; 152(5):1090-1099.e1. PubMed ID: 28088461
[TBL] [Abstract][Full Text] [Related]
4. HBV infection is associated with greater mortality in hospitalised patients compared to HCV infection or alcoholic liver disease.
Rajbhandari R; Danford CJ; Chung RT; Ananthakrishnan AN
Aliment Pharmacol Ther; 2015 May; 41(10):928-38. PubMed ID: 25786514
[TBL] [Abstract][Full Text] [Related]
5. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009.
Younossi ZM; Otgonsuren M; Henry L; Venkatesan C; Mishra A; Erario M; Hunt S
Hepatology; 2015 Dec; 62(6):1723-30. PubMed ID: 26274335
[TBL] [Abstract][Full Text] [Related]
6. The Global Burden of Liver Disease.
Younossi ZM; Wong G; Anstee QM; Henry L
Clin Gastroenterol Hepatol; 2023 Jul; 21(8):1978-1991. PubMed ID: 37121527
[TBL] [Abstract][Full Text] [Related]
7. Clinical Patterns and Outcome of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease.
Ahn SY; Kim SB; Song IH
Can J Gastroenterol Hepatol; 2020; 2020():4873875. PubMed ID: 32566546
[TBL] [Abstract][Full Text] [Related]
8. Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD.
Paik JM; Golabi P; Younossi Y; Mishra A; Younossi ZM
Hepatology; 2020 Nov; 72(5):1605-1616. PubMed ID: 32043613
[TBL] [Abstract][Full Text] [Related]
9. Trends in hospitalizations for chronic liver disease-related liver failure in the United States, 2005-2014.
Kim D; Cholankeril G; Li AA; Kim W; Tighe SP; Hameed B; Kwo PY; Harrison SA; Younossi ZM; Ahmed A
Liver Int; 2019 Sep; 39(9):1661-1671. PubMed ID: 31081997
[TBL] [Abstract][Full Text] [Related]
10. Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without non-alcoholic fatty liver disease.
Wong CR; Njei B; Nguyen MH; Nguyen A; Lim JK
Aliment Pharmacol Ther; 2017 Dec; 46(11-12):1061-1069. PubMed ID: 28960360
[TBL] [Abstract][Full Text] [Related]
11. Etiological Patterns, Liver Fibrosis Stages and Prescribing Patterns of Hepato-Protective Agents in Indian Patients with Chronic Liver Disease.
Choudhuri G; Chaudhari S; Pawar D; Roy DS
J Assoc Physicians India; 2018 Dec; 66(12):58-63. PubMed ID: 31315327
[TBL] [Abstract][Full Text] [Related]
12. Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US veterans, 2001-2013.
Beste LA; Leipertz SL; Green PK; Dominitz JA; Ross D; Ioannou GN
Gastroenterology; 2015 Nov; 149(6):1471-1482.e5; quiz e17-8. PubMed ID: 26255044
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for HCC in contemporary cohorts of patients with cirrhosis.
Kanwal F; Khaderi S; Singal AG; Marrero JA; Loo N; Asrani SK; Amos CI; Thrift AP; Gu X; Luster M; Al-Sarraj A; Ning J; El-Serag HB
Hepatology; 2023 Mar; 77(3):997-1005. PubMed ID: 35229329
[TBL] [Abstract][Full Text] [Related]
14. Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification.
Ioannou GN; Green P; Kerr KF; Berry K
J Hepatol; 2019 Sep; 71(3):523-533. PubMed ID: 31145929
[TBL] [Abstract][Full Text] [Related]
15. Trends in the Burden of Chronic Liver Disease Among Hospitalized US Adults.
Hirode G; Saab S; Wong RJ
JAMA Netw Open; 2020 Apr; 3(4):e201997. PubMed ID: 32239220
[TBL] [Abstract][Full Text] [Related]
16. Comparing clinical presentations, treatments and outcomes of hepatocellular carcinoma due to hepatitis C and non-alcoholic fatty liver disease.
Than NN; Ghazanfar A; Hodson J; Tehami N; Coldham C; Mergental H; Manas D; Shah T; Newsome PN; Reeves H; Shetty S
QJM; 2017 Feb; 110(2):73-81. PubMed ID: 27634970
[TBL] [Abstract][Full Text] [Related]
17. Sarcopenia, healthy living, and mortality in patients with chronic liver diseases.
Van Dongen C; Paik JM; Harring M; Younossi Y; Price JK; Kabbara K; Golabi P; Younossi ZM
Hepatol Commun; 2022 Nov; 6(11):3140-3153. PubMed ID: 35950286
[TBL] [Abstract][Full Text] [Related]
18. Anti-HCV positive hepatocellular carcinoma in cirrhosis. Prevalence, risk factors and clinical features.
Farinati F; Fagiuoli S; De Maria N; Chiaramonte M; Aneloni V; Ongaro S; Salvagnini M; Naccarato R
J Hepatol; 1992 Mar; 14(2-3):183-7. PubMed ID: 1380021
[TBL] [Abstract][Full Text] [Related]
19. Causes of death in patients with Non-alcoholic Fatty Liver Disease (NAFLD), alcoholic liver disease and chronic viral Hepatitis B and C.
Golabi P; Paik JM; Eberly K; de Avila L; Alqahtani SA; Younossi ZM
Ann Hepatol; 2022; 27(1):100556. PubMed ID: 34800721
[TBL] [Abstract][Full Text] [Related]
20. Impact of diabetes, obesity, and dyslipidemia on the risk of hepatocellular carcinoma in patients with chronic liver diseases.
Shin HS; Jun BG; Yi SW
Clin Mol Hepatol; 2022 Oct; 28(4):773-789. PubMed ID: 35934813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
